血pTau181和粉样蛋白标记物预测在异常REM睡眠行为障碍中转化为痴呆症
Aline Delva1,2, Amélie Pelletier3,4, Emma Somerville1,5
1The Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, QC H3A 2B4, Canada.
Brain : a journal of neurology
|January 6, 2025
概括
包括粉样β (Aβ) 和pTau181在内的血生物标志物可以预测患有异常/孤立REM睡眠行为障碍 (iRBD) 个体的勒维体痴呆症 (DLB). 这一发现有助于早期诊断神经退行性疾病.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物发现发现
- 神经学 神经学
背景情况:
- 阿尔茨海默氏病 (AD) 病理学经常伴随着痴呆症与莱维体 (DLB) 的共同疾病.
- 异常/孤立的REM睡眠行为障碍 (iRBD) 是同核蛋白病变的早期迹象,包括DLB.
- 在iRBD中对DLB进行预测的生物标志物对于早期干预是必要的.
研究的目的:
- 调查血氨基酸β (Aβ) 和pTau181水平是否可以预测iRBD患者的DLB发展.
- 评估基线血生物标志物与随后的DLB转化之间的关联.
主要方法:
- 进行了一项长度队列研究,对158名经过多睡眠学确认的IRBD患者进行了研究.
- 在基线测量了血Aβ40,Aβ42和pTau181水平.
- 对参与者进行了前性跟踪,以观察他们是否转变为神经退行性综合征,其中DLB是主要结果.
主要成果:
- 与非转换者相比,转换为DLB的个体表现出明显较低的基线血Aβ42 / 40比率和较高的pTau181水平.
- 血pTau181水平也与各个领域的认知测试表现相关.
- 在iRBD患者中,Aβ42/40比率和pTau181水平是DLB转换的显著预测指标.
结论:
- 血Aβ42 / 40比率和pTau181是有希望的基于血液的生物标志物,用于预测iRBD患者的DLB发展.
- 这些生物标志物可能有助于更早地诊断和管理DLB.
- 需要进一步的研究来验证这些发现在更大,更多样化的队列中.
相关概念视频
01:15REM Sleep Behavior Disorder
140
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
140
01:26Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
01:22Alzheimer's Disease: Treatment
161
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
161